Table 2.
Summary of clinical outcome of all patients who received Ikervis and the dosing frequency used, categorised into five indications (total n=463 patients)
| DED | AED | OMMP/SJS | Post-graft | Others | P value* | |
| Total n=322 | Total n=53 | Total n=38 | Total n=14 | Total n=36 | ||
| n (%) | n (%) | n (%) | n (%) | n (%) | ||
| Outcome | ||||||
| Resolved | 98 (30.4) | 6 (11.3) | 1 (2.6) | 1 (7.1) | 13 (36.1) | <0.001 |
| Stable | 166 (51.6) | 14 (26.4) | 24 (63.2) | 6 (42.9) | 14 (38.9) | <0.001 |
| Active | 21 (6.5) | 11 (20.8) | 2 (5.3) | 7 (50.0) | 3 (8.3) | <0.001 |
| Intolerant | 37 (11.5) | 22 (41.5) | 11 (28.9) | 0 (0.0) | 6 (16.7) | <0.001 |
| Ikervis frequency | 0.007† | |||||
| Once a day | 212 (65.8) | 28 (52.8) | 21 (55.3) | 3 (21.4) | 22 (61.1) | |
| Twice a day | 110 (34.2) | 23 (43.4) | 17 (44.7) | 9 (64.3) | 13 (36.1) | |
| >Twice a day | 0 | 1 (1.9) | 0 | 2 (1.43) | 1 (2.8) | |
| Treatment duration, months‡ | 12.1±6.4 | 18.7±8.1 | 10 | 24 | 11.5±10.4 | 0.08 |
*Comparison was made among the five indications for each clinical outcome.
†χ2 test was performed to compare the difference among the five indications between group 1 (once a day group) and group 2 (twice a day and >twice a day groups).
‡Treatment duration, presented in mean±SD, refers to the duration of Ikervis used to achieve resolution of the disease. ANOVA test was performed to examine the difference among DED, AED and others groups.
AED, allergic eye disease (which included vernal and atopic keratoconjunctivitis; DED, dry eye disease; OMMP, ocular mucous membrane pemphigoid; SJS, Steven-Johnson syndrome.